NASDAQ:GANX Gain Therapeutics Q2 2025 Earnings Results & Report $1.04 -0.04 (-3.70%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.06 +0.02 (+1.73%) As of 11/13/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Gain Therapeutics missed analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.19 versus the -$0.17 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call4:00 PM ET Gain Therapeutics EPS ResultsActual EPS-$0.19Consensus EPS -$0.17Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersGain Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Gain Therapeutics Q2 2025 Earnings FAQ Did Gain Therapeutics beat earnings estimates for Q2 2025? Gain Therapeutics (NASDAQ:GANX) reported earnings of -$0.19 per share for Q2 2025, missing the consensus estimate of -$0.17. The report was announced on Tuesday, August 12, 2025. Gain Therapeutics Earnings HeadlinesGain Therapeutics Q3 Loss NarrowsNovember 10, 2026 | rttnews.comGain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateNovember 10, 2026 | globenewswire.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 15 at 1:00 AM | Traders Agency (Ad)Gain Therapeutics (GANX) Projected to Announce Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comGain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific ConferencesNovember 5, 2026 | globenewswire.comSibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to ClinicOctober 13, 2026 | globenewswire.comSee More Gain Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email. Email Address About Gain TherapeuticsGain Therapeutics (NASDAQ:GANX) is a biotechnology company developing small-molecule treatments for neurological and other diseases linked to dysfunctional proteins. Its research focuses on conditions for which existing therapies may not address the underlying protein dysfunction. The company uses its discovery platform, which combines computational methods and structural biology, to identify previously unexplored binding sites on proteins. It aims to develop compounds that bind at these sites and help restore protein function. Gain Therapeutics’ lead program, GT-02287, is an oral investigational therapy being developed for Parkinson’s disease, including disease associated with GBA1 mutations. The company is also pursuing drug-discovery programs for other neurological and lysosomal disorders.View Gain Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay UnconvincedYETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine Is Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
